ANIX News - Candlesense

Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology

Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer Vaccine Expands global intellectual property coverage in markets with high breast cancer incidence New patent will...

What is the timing and likelihood of commercialization of the breast cancer vaccine in China, and how might it influence the stock's volatility? What competitive advantage does this IP protection give Anixa versus other breast cancer vaccine developers in China and globally? How will the new Chinese patent approval affect Anixa Biosciences' revenue forecasts and valuation?

Patents

4 days ago

Read more prnewswire

Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial

Fourth Cohort Receiving 30x Initial Dose with No Dose-Limiting Toxicities Observed to Date SAN JOSE, Calif., Aug. 18, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ...

How does Anixa’s CAR‑T progress compare to competing ovarian cancer immunotherapies, and what market share potential does it create if the trial continues to succeed? What immediate impact could this trial update have on ANIX’s stock price and trading volume, considering market expectations and analyst sentiment? How will the lack of dose‑limiting toxicities and the higher 30x dose in the fourth cohort influence the likelihood and timeline of regulatory approval for Anixa’s ovarian cancer CAR‑T therapy?

Clinical trials

6 days ago

Read more prnewswire

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ...

How does this patent issuance align with broader industry trends in solid‑tumor CAR‑T research and development? What impact could the extended patent have on the company's ability to raise capital or secure debt financing? Is there any risk of patent challenges or prior‑art disputes that could offset the perceived benefits?

Patents

12 days ago

Read more prnewswire

Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference

Dr. Wenham is Principal investigator on Anixa's CAR-T therapy for Ovarian Cancer SAN JOSE, Calif., Aug. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a ...

How does the sentiment score of 70 influence market perception, and could it lead to a re‑rating by analysts? Are there any indications of additional indications or expansion of the CAR‑T technology beyond ovarian cancer? What is the anticipated impact of the conference news on short‑term trading volume and price volatility for ANIX?

Clinical trials

16 days ago

Read more prnewswire